Novarel market forecast points to faster growth in Asia-Pacific

The Business Research Company says the Novarel market will expand through 2035 as infertility rates rise, fertility treatments spread and healthcare spending increases. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Novarel sits inside a larger fertility-treatment market that is being pushed by rising infertility, advanced reproductive care and more outpatient treatment options. - The market outlook matters for fertility clinics, reproductive health providers and drug makers tied to hCG-based therapies. - The report also points to shifting demand by region, with Asia-Pacific expected to outpace other markets.

What happened: - The Business Research Company published a Novarel market report covering market size, trends and a global forecast for 2026-2035. - The report says Novarel market growth has been supported by more fertility treatment centers, wider use of hCG therapies and more injectable hormone formulations. - The report says North America was the largest Novarel market in 2025. - The report says Asia-Pacific is forecast to be the fastest-growing region over the coming years. - The report includes coverage of Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Novarel is a brand of medication containing human chorionic gonadotropin, or hCG. - Novarel is used in fertility treatment to regulate ovulation in women and support testosterone production in men. - The medication is administered by injection and is monitored by healthcare professionals. - The report links future growth to greater use of advanced fertility methods and the increasing age of mothers. - The report also points to personalized fertility protocols, more investment in reproductive health services and stronger demand for outpatient fertility treatment. - The company says fertility hormone therapy use is rising, alongside more frequent use of injectable gonadotropins such as Novarel. - The report says clinical customization is improving the ability to tailor fertility treatment to individual patients. - The report says that approach is expected to improve treatment effectiveness and patient outcomes over time. - The report cites infertility as a major demand driver, defining it as the inability to conceive after one year of regular, unprotected sexual activity or to carry a pregnancy to term. - The World Health Organization reported in April 2023 that about 17.5% of adults globally, or roughly one in six people, experience infertility. - Rising healthcare spending is another driver cited in the report, supported by aging populations, more chronic disease and medical technology advances. - The UK Office for National Statistics reported in May 2024 that total healthcare spending rose 5.6% nominally from 2022 to 2023. - The report says more drug approvals are also helping the market by increasing clinical availability of therapies. - ClinicalTrials.gov recorded 39,710 new clinical studies in 2023, bringing the total to 477,203, up from 38,023 new studies in 2022. - The report adds new 2026 features including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also includes key technologies and future trend analysis. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The report frames Novarel as a niche but growing part of the fertility market, with demand tied more to broader reproductive-health trends than to one product cycle. - The regional split suggests mature markets are still important, but future expansion may come faster from places where fertility care is scaling up. - The focus on personalization suggests clinics are moving toward more tailored hormone protocols rather than one-size-fits-all treatment.

What's next: - The report expects continued market expansion through 2035 as fertility care becomes more advanced and more widely used. - The Asia-Pacific region is expected to be the main growth engine in the next phase of the market. - The added forecasting tools and trend analysis signal that buyers and investors will likely use the report for planning, benchmarking and opportunity screening.